Vedolizumab in the treatment of chronic, antibiotic‐dependent or refractory pouchitis
Alimentary Pharmacology & Therapeutics2017Vol. 47(5), pp. 581–587
Citations Over TimeTop 10% of 2017 papers
Florian Bär, Tanja Kühbacher, N.A. Dietrich, T Krause, Andreas Stallmach, Niels Teich, Stefan Schreiber, Jens Walldorf, Renate Schmelz, Carsten Büning, Klaus Fellermann, Jürgen Büning, Ulf Helwig, the German IBD Study Group
Abstract
Our data indicate that vedolizumab could be an option in the treatment of patients with chronic, antibiotic-dependent or refractory pouchitis.
Related Papers
- → Circulating soluble adhesion molecules in inflammatory bowel disease(1995)79 cited
- → Vedolizumab for the treatment of ulcerative colitis(2015)2 cited
- → Hypothesis-pouchitis represents a useful clinical model of ulcerative colitis(1994)5 cited
- → The Microbiome Profile In Ulcerative Colitis And Pouchitis(2021)
- → Research in Brief(2023)